91724-94-6

Basic information

• Product Name: 5-methyl-3-(propan-2-yl)-1H-pyrazole
• CAS NO: 91724-94-6
• Molecular Weight: 124.186
• Mol File: 91724-94-6.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 5-methyl-3-(propan-2-yl)-1H-pyrazole(CAS DataBase Reference)
• NIST Chemistry Reference: 5-methyl-3-(propan-2-yl)-1H-pyrazole(91724-94-6)
• EPA Substance Registry System: 5-methyl-3-(propan-2-yl)-1H-pyrazole(91724-94-6)

Safety Data

• Hazardous Substances Data: 91724-94-6(Hazardous Substances Data)

Upstream product

• 1056174-70-9 (1E)-1-(dimethylamino)-2,4-dimethylpent-1-en-3-one 
• 7307-03-1 5-methylhexane-2,4-dione 

Relevant articles and documents

Discovery and SAR Evolution of Pyrazole Azabicyclo[3.2.1]octane Sulfonamides as a Novel Class of Non-CovalentN-Acylethanolamine-Hydrolyzing Acid Amidase (NAAA) Inhibitors for Oral Administration

Inhibition of intracellularN-acylethanolamine-hydrolyzing acid amidase (NAAA) activity is a promising approach to manage the inflammatory response under disabling conditions. In fact, NAAA inhibition preserves endogenous palmitoylethanolamide (PEA) from degradation, thus increasing and prolonging its anti-inflammatory and analgesic efficacy at the inflamed site. In the present work, we report the identification of a potent, systemically available, novel class of NAAA inhibitors, featuring a pyrazole azabicyclo[3.2.1]octane structural core. After an initial screening campaign, a careful structure-activity relationship study led to the discovery ofendo-ethoxymethyl-pyrazinyloxy-8-azabicyclo[3.2.1]octane-pyrazole sulfonamide50(ARN19689), which was found to inhibit human NAAA in the low nanomolar range (IC50= 0.042 μM) with a non-covalent mechanism of action. In light of its favorable biochemical, in vitro and in vivo drug-like profile, sulfonamide50could be regarded as a promising pharmacological tool to be further investigated in the field of inflammatory conditions.

PYRROLO[2,3-D]PYRIMIDINE TROPOMYOSIN-RELATED KINASE INHIBITORS

The present invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as Trk antagonists.